文献速递脑血管病

血小板功能监测指导抗血小板治疗对颅内动脉瘤支架术后缺血事件的影响

Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms.
PubMed 文献 · Stroke · 2021-09-20

该随机、开放标签、平行组、评估者盲试验纳入314例未破裂颅内动脉瘤支架置入患者,比较血小板功能监测指导的药物调整与常规治疗。监测组主要复合缺血终点和缺血性卒中的发生率均显著低于常规组,但轻微或极小出血事件显著增加,大出血无显著差异。

要点

  • 监测指导调整抗血小板治疗可降低支架术后7天内缺血性卒中及复合缺血事件。
  • 监测组轻微或极小出血事件发生率显著高于常规组,但大出血无显著差异。
  • 该策略适用于未破裂颅内动脉瘤支架置入患者,需权衡缺血与出血风险。

核心结论

  • 血小板功能监测指导的抗血小板治疗可减少未破裂颅内动脉瘤支架置入后的血栓栓塞事件。
  • 该策略显著增加轻微或极小出血事件,但不增加大出血事件。

研究设计与样本

  • 随机、开放标签、平行组、评估者盲试验,纳入314例未破裂颅内动脉瘤支架置入患者,1:1分配至药物调整组或常规治疗组,每组157例。
  • 药物调整组依据血小板功能监测发现高治疗中血小板反应性后调整抗血小板药物,随机化后14天进行第二次监测。

主要发现

  • 主要复合终点(缺血性卒中、短暂性脑缺血发作、支架内血栓形成、紧急血运重建和脑血管死亡)在常规组发生19例(12.1%),监测组8例(5.1%)(HR 0.39,95%CI 0.17-0.92;P=0.03)。
  • 缺血性卒中在监测组发生率低于常规组(4.5% vs 12.1%;HR 0.34,95%CI 0.14-0.83;P=0.01),驱动了主要复合终点的总体差异。
  • 安全终点(支架置入后1个月内大、小或极小出血复合频率)在监测组为7.0%,常规组为1.9%(HR 3.87,95%CI 1.06-14.14;P=0.03)。
  • 轻微或极小出血事件频率两组差异显著(监测组6.4% vs 常规组1.3%;P=0.02),大出血事件频率两组无显著差异。

关键数值与推荐

  • 主要终点为支架置入后7天内缺血性卒中、短暂性脑缺血发作、支架内血栓形成、紧急血运重建和脑血管死亡的复合频率。
  • 安全终点为支架置入后1个月内大、小或极小出血的复合频率。

临床怎么用

  • 对于未破裂颅内动脉瘤支架置入患者,可考虑采用血小板功能监测指导抗血小板治疗以降低围手术期缺血事件。
  • 应用该策略时需注意轻微或极小出血风险增加,但大出血风险未见显著升高。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: This study tests whether patients with unruptured intracranial aneurysm who underwent stent placement benefitted from platelet function monitoring-guided adjustment of antiplatelet therapy. METHODS: We conducted a randomized, open-label, parallel group, assessor-blinded trial. Patients with unruptured intracranial aneurysm who underwent stent placement were assigned in a 1:1 ratio to receive either drug adjustment (patients who had high on-treatment platelet reactivity to antiplatelet therapy on the basis of platelet function monitoring [monitoring group]) or conventional therapy (without monitoring and drug adjustment [conventional group]). The second monitoring was performed 14 days after randomization in patients with drug adjustment. The primary outcome was the composite frequency of ischemic stroke, transient ischemic attack, stent thrombosis, urgent revascularization, and cerebrovascular death within 7 days after stent implantation. The safety outcome was the composite frequency of major, minor, or minimal bleeding within 1 month after stent implantation. RESULTS: In total, 314 patients were included (n=157 per group). The primary combined outcome occurred in 19 patients (12.1%) in the conventional group and 8 patients (5.1%) in the monitoring group (hazard ratio, 0.39 [95% CI, 0.17-0.92]; P=0.03). Ischemic stroke occurred at a lower frequency in the monitoring group compared with that in the conventional group (4.5% versus 12.1%; hazard ratio, 0.34 [95% CI, 0.14-0.83]; P=0.01), which drove the overall primary combined outcome. The safety outcome occurred in the monitoring group (7.0%) and in the conventional group (1.9%; hazard ratio, 3.87 [95% CI, 1.06-14.14]; P=0.03). A significant difference was observed in the frequency of minor or minimal bleeding events between the two groups (monitoring group versus conventional group, 6.4% versus 1.3%; P=0.02) but not in the frequency of major bleeding events between the two groups. CONCLUSIONS: Platelet function monitoring-guided antiplatelet therapy reduces thromboembolic events in patients with unruptured intracranial aneurysm after stent placement, significantly enhancing minor or minimal bleeding events but not major bleeding events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03989557.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Li W, Zhu W, Wang A, et al. Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events After Stenting for Intracranial Aneurysms. Stroke. 2021. PMID: 34538087. doi:10.1161/STROKEAHA.120.032989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。